Open access
Oct 2026
Evolving demographic representation and patient-reported outcomes in landmark antibody-drug conjugate trials supporting FDA approvals, 2015-2026.
166 Background: Antibody-drug conjugates (ADCs) combine targeted delivery with potent cytotoxic payloads and are rapidly reshaping standard of care across solid and hematologic malignancies. As ADC use expand into earlier lines and broader populations, adequate representation of patients treated in real-world p...
Nitya Batra, Y. Ammakola, A. Khosla et al.
· JCO Oncology Practice · 0 citations